Skip to main content

6-K

GSK plc (GSK)

6-K 2020-11-27 For: 2020-11-27
View Original
Added on April 10, 2026

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of November 2020

Commission File Number 001-15170

GlaxoSmithKline plc

(Translation of registrant's name into English)

980 Great West Road, Brentford, Middlesex, TW8 9GS

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F . . . .X. . . . Form 40-F . . . . . . . .

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____

GlaxoSmithKline plc

GSK publishes provisional dividend dates

GSK announces the following dividend dates for 2021:

Results Announcement date Ex-dividend date Record date Last date for DRIP elections Payable
Q1 2021 Wednesday 28 April 2021 Thursday 20 May 2021 Friday 21 May 2021 Thursday 17 June 2021 Thursday 8 July 2021
Q2 2021 Wednesday 28 July 2021 Thursday 19 August 2021 Friday 20 August 2021 Thursday 16 September 2021 Thursday 7 October 2021
Q3 2021 Wednesday 27 October 2021 Thursday 18 November 2021 Friday 19 November 2021 Monday 20 December 2021 Thursday 13 January 2022
Q4<br>2021<br><br><br>(Final) Wednesday 9 February 2022 Thursday 24 February 2022 Friday 25 February 2022 Thursday 17 March 2022 Thursday 7 April 2022

These dates are indicative and may be subject to change.

V A Whyte

Company Secretary

27 November 2020

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc
(Registrant)
Date: November<br>27, 2020
By:/s/ VICTORIA<br>WHYTE<br><br><br>--------------------------
Victoria Whyte
Authorised<br>Signatory for and on
behalf<br>of GlaxoSmithKline plc